Connect with us

Whether you’re taking AQVESME or want to learn more, sign up to connect with an Agios Clinical Educator (ACE) and to receive additional information on upcoming educational programs and resources. ACEs provide one-on-one disease education and support in understanding AQVESME. THIS IS FOR US RESIDENTS ONLY.

You can also call 1-877-77-AGIOS (1-877-772-4467) Mon-Fri, 8 AM to 8 PM ET to get started with myAgios® Patient Support Services.

ACEs do not provide medical advice. For medical advice or treatment-related questions, please talk to your healthcare team.

*Required field

Are you a US resident?*
Tell us about yourself.*
Have you had a conversation with your doctor about AQVESME?
I would like an Agios representative to share educational information about thalassemia or
AQVESME with my US-based physician or healthcare professional who treats thalassemia.

By clicking “SUBMIT,” I agree to (you must choose at least one):

  • By selecting “one-on-one conversations” I consent that Agios and its agents (ACE/PSM) will contact me via email or at the number I provided below (Phone/SMS/Text†) and send me information about AQVESME, thalassemia or answer my questions about living with thalassemia
  • I attest that I am eligible to participate in this program:
  • I have been diagnosed with thalassemia or I am a caregiver/advocate for a person diagnosed with thalassemia
  • I understand I will receive educational information about thalassemia or AQVESME, opportunities to join research, or other updates from Agios
  • I am at least 18 years old and a US resident

Agios understands protecting your personally identifiable information is very important. Agios does not share personally identifiable information you share with us during our phone, SMS/Text, or e-mail communications with third parties other than Agios’ vendors who perform services on Agios’ behalf.

Consent to Receive Communications

†

If I select the “one-on-one conversations” checkbox above, I consent to receive email, text messages and/or phone calls, respectively, from Agios (or those acting on its behalf) for marketing, operational and informational purposes, such as support and educational resources on AQVESME and thalassemia as well as research opportunities, and other information that may be of interest to me. Text messages and phone calls may be generated using automated technology and will be made to the phone number provided on this form. I may opt out of text messages at any time by replying “STOP” to the number from which I received the text message. I can also unsubscribe from phone calls and text messages by calling 1-877-77-AGIOS (1-877-772-4467), and I can unsubscribe from promotional e-mails by clicking “unsubscribe” in one of Agios’ promotional e-mails.

By clicking “SUBMIT,” I agree to the electronic signature terms and conditions presented in the Agreement to Receive Disclosures and Consent Electronically. I understand and agree that the information I provide will be used in accordance with the Agios Privacy Policy, including to provide me with marketing information, offers, and promotions, and to contact me for my opinions regarding Agios products, programs, and services.

IMPORTANT SAFETY INFORMATION

AQVESME may cause serious side effects, including:

  • Liver injury. AQVESME can cause serious liver injury. Liver injury has happened in people with thalassemia within the first 6 months of treatment with AQVESME. Your healthcare provider will do blood tests to check your liver before you start treatment with AQVESME, every 4 weeks for the first 24 weeks of treatment, and as needed. Your healthcare provider may temporarily or permanently stop your treatment with AQVESME if you have abnormal liver blood tests.

    Tell your healthcare provider right away if you develop any new or worsening signs or symptoms of liver problems, including:

    • loss of appetite
    • nausea
    • pain in the upper right side of your stomach area
    • vomiting
    • yellowing of the skin and white part of your eyes (jaundice)
    • dark-colored urine

In clinical studies of AQVESME, 2 of 301 people (0.66%) treated with AQVESME experienced adverse reactions suggestive of liver injury. Three additional people experienced adverse reactions suggestive of liver injury during the open-label extension periods, after switching from placebo to AQVESME. Of the 5 people, two had serious liver injury requiring hospitalization, including 1 who developed jaundice. Another developed jaundice without requiring hospitalization. All 5 people discontinued treatment with AQVESME, and these reactions improved upon treatment discontinuation.

Because of the risk for liver injury, AQVESME is only available through a restricted access program called the AQVESME Risk Evaluation and Mitigation Strategy (REMS).

Before taking AQVESME, tell your healthcare provider about all of your medical conditions, including if you:

  • have liver problems, such as cirrhosis
  • are pregnant or plan to become pregnant. It is not known if AQVESME will harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think that you are pregnant during treatment with AQVESME.
  • are breastfeeding or plan to breastfeed. It is not known if AQVESME passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with AQVESME.

Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Make sure to tell your healthcare provider if you take or use hormonal birth control (contraceptives). If you take or use hormonal birth control (except for intrauterine systems containing levonorgestrel), it may not work as well during treatment with AQVESME. Use a different type of birth control or use an additional nonhormonal birth control method (such as condoms) during treatment with AQVESME and for 28 days after stopping treatment with AQVESME. AQVESME and certain other medicines may affect each other and cause side effects. AQVESME may affect the way other medicines work, and other medicines may affect the way AQVESME works.

The most common side effects of AQVESME in patients:

  • headache
  • insomnia

These are not all of the possible side effects of AQVESME. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is AQVESME?

AQVESME is a prescription medicine used to treat anemia (low red blood cells) in adults with alpha- or beta-thalassemia. It is not known if AQVESME is safe and effective in children.

Please see full Prescribing Information, including Medication Guide.

IMPORTANT SAFETY INFORMATION

AQVESME may cause serious side effects, including:

  • Liver injury. AQVESME can cause serious liver injury. Liver injury has happened in people with thalassemia within the first 6 months of treatment with AQVESME. Your healthcare provider will do blood tests to check your liver before you start treatment with AQVESME, every 4 weeks for the first 24 weeks of treatment, and as needed. Your healthcare provider may temporarily or permanently stop your treatment with AQVESME if you have abnormal liver blood tests.

    Tell your healthcare provider right away if you develop any new or worsening signs or symptoms of liver problems, including:

    • loss of appetite
    • nausea
    • pain in the upper right side of your stomach area
    • vomiting
    • yellowing of the skin and white part of your eyes (jaundice)
    • dark-colored urine

In clinical studies of AQVESME, 2 of 301 people (0.66%) treated with AQVESME experienced adverse reactions suggestive of liver injury. Three additional people experienced adverse reactions suggestive of liver injury during the open-label extension periods, after switching from placebo to AQVESME. Of the 5 people, two had serious liver injury requiring hospitalization, including 1 who developed jaundice. Another developed jaundice without requiring hospitalization. All 5 people discontinued treatment with AQVESME, and these reactions improved upon treatment discontinuation.

Because of the risk for liver injury, AQVESME is only available through a restricted access program called the AQVESME Risk Evaluation and Mitigation Strategy (REMS).

Before taking AQVESME, tell your healthcare provider about all of your medical conditions, including if you:

  • have liver problems, such as cirrhosis
  • are pregnant or plan to become pregnant. It is not known if AQVESME will harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think that you are pregnant during treatment with AQVESME.
  • are breastfeeding or plan to breastfeed. It is not known if AQVESME passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with AQVESME.

Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Make sure to tell your healthcare provider if you take or use hormonal birth control (contraceptives). If you take or use hormonal birth control (except for intrauterine systems containing levonorgestrel), it may not work as well during treatment with AQVESME. Use a different type of birth control or use an additional nonhormonal birth control method (such as condoms) during treatment with AQVESME and for 28 days after stopping treatment with AQVESME. AQVESME and certain other medicines may affect each other and cause side effects. AQVESME may affect the way other medicines work, and other medicines may affect the way AQVESME works.

The most common side effects of AQVESME in patients:

  • headache
  • insomnia

These are not all of the possible side effects of AQVESME. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is AQVESME?

AQVESME is a prescription medicine used to treat anemia (low red blood cells) in adults with alpha- or beta-thalassemia. It is not known if AQVESME is safe and effective in children.

Please see full Prescribing Information, including Medication Guide.